3069
ChinaAMC Hang Seng Hong Kong Biotech ETF
NAV as of
4 Week: 7.25 - 8.10
52 Week: 7.25 - 12.79
Latest Closing Price
7.82
Premium / Discount
0.06
Expense Ratio
-
Investment Objective
The investment objective of the Sub-Fund is to provide investment results that, before fees and expenses, closely correspond tothe performance of the Index. There can be no assurance that the Sub-Fund will achieve its investment objective.
Main Fund Characteristics
Performance
Period | Performance Returns(%) | Volatility(%) | Risk Adjusted Performance |
---|---|---|---|
YTD | -23.26 | 2.41 | -9.66 |
1 Day | 1.28 | 0.00 | 0.00 |
1 Week | 6.45 | 4.91 | 1.31 |
1 Month | -3.18 | 7.40 | -0.43 |
3 Months | -10.81 | 18.78 | -0.58 |
6 Months | -22.12 | 25.88 | -0.85 |
1 Year | -36.54 | 34.40 | -1.06 |
2 Years | -28.97 | 52.71 | -0.55 |
3 Years | -69.42 | 68.81 | -1.01 |
5 Years | 0.00 | 0.00 | 0.00 |
10 Years | 0.00 | 0.00 | 0.00 |
Price History
Annual Performance Return
2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
Price (%) | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | -18.3092 | -23.5927 |
Nav (%) | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 |
Rank | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 71.0000 | 99.0000 |
Dividend Frequency
Lastest Dividend
Ex Date | Payment Date | Dividend Payout per unit |
---|---|---|
18/12/2022 | 29/12/2022 | 0.0400 |
Portfolio Data
Total Number of Holdings: 50
Number of Bond Holdings: 0
Number of Equity Holdings: 50
Total Market Value: 622,783,523
Portfolio Composition
Top 10 Holdings
% Portfolio Weight | Shares Owned | Shares Changed | Market Value | ||
---|---|---|---|---|---|
1 | BeiGene Ltd Ordinary Shares | 10.9856 | 621,403 | 165,218 | 68,416,470 |
2 | CSPC Pharmaceutical Group Ltd | 9.4160 | 8,077,269 | 115,714 | 58,640,973 |
3 | Innovent Biologics Inc | 8.5000 | 1,238,286 | 70,360 | 52,936,726 |
4 | WuXi Biologics (Cayman) Inc | 7.1322 | 1,500,605 | 216,054 | 44,417,908 |
5 | Sino Biopharmaceutical Ltd | 5.6862 | 10,205,339 | 140,730 | 35,412,526 |
6 | Wuxi AppTec Co Ltd | 4.1812 | 327,750 | 4,608 | 26,039,738 |
7 | Genscript Biotech Corp Class H | 3.9752 | 1,246,555 | 19,288 | 24,756,582 |
8 | Akeso Inc Ordinary Shares | 3.9709 | 532,979 | 45,762 | 24,730,226 |
9 | JD Health International Inc | 3.1610 | 503,486 | 7,184 | 19,686,303 |
10 | Zai Lab Ltd Ordinary Shares | 3.0869 | 894,162 | 16,686 | 19,224,483 |
Country Exposure
Regional Exposure
America
Greater Europe
Greater Asia
Market Classification
Market Capitalization
Size | % of portfolio |
---|---|
Giant | 15.17 |
Large | 57.22 |
Medium | 22.81 |
Small | 4.63 |
Micro | 0.17 |
Equity Style Box Breakdown
0 | 0 | 0 | Large |
0 | 0 | 0 | Mid |
0 | 0 | 0 | Small |
Value | Blend | Growth |
Value Measures
Price/Prospective Earnings*
13.5302
Price/Book*
2.1845
Price/Sales*
1.3451
Price/Cash Flow*
10.0500
Dividend Yield*
1.3885
Growth Measures
Long-Term Earnings
12.1753
Historical Earnings
1.7155
Sales Growth
9.0928
Cash-Flow Growth
-2.9424
Book-Value Growth
8.6404
*Forward-looking based on historical data.
Equity Sector
Number of Bond Holdings
0
Bond Statitics
Detail | Value |
---|---|
Average Effective Duration | 0 |
Average Effective Maturity (Years)* | 0 |
Average Credit Quality | 0 |
Average Weighted Coupon* | 0 |
Average Weighted Price* | 0 |
Bond Style Box Breakdown
0 | 0 | 0 | High | Quality |
0 | 0 | 0 | Med | |
0 | 0 | 0 | Low | |
Ltd | Mod | Ext | ||
Interest-Rate Sensitivity |
Credit Quality
Type | % Bonds |
---|---|
N.A |
Bond Sector
Bond Maturity
% Bonds | |
---|---|
N.A |
Data Source: Morningstar
© 2019 Morningstar. All Rights Reserved. The information, data, analyses and opinions (“Information”) contained herein:
(2) may not be copied or redistributed except as specifically authorised;
(3) do not constitute investment advice;
(4) are provided solely for informational purposes;
(5) are not warranted to be complete, accurate or timely; and
(6) may be drawn from fund data published on various dates.
Morningstar and Phillip Securities Pte Ltd are not responsible for any trading decisions, damages or other losses related to the Information or its use. Please verify all of the Information before using it and don’t make any investment decision except upon the advice of a professional financial adviser. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up.
For the most up-to-date fund’s data and information, a copy of the fund factsheet, information or prospectus may be obtained from the respective ETF issuer.